Researchers at the Seaver Autism Center for Research and Treatment at Mount Sinai School of Medicine and Columbia University wanted to determine if oxytocin, popularly dubbed the “hormone of love,” could have widespread benefit in making us more understanding of others.
They conducted a randomized, double-blind, placebo-controlled, cross-over challenge, giving 27 healthy adult men oxytocin or a placebo delivered nasally. Participants then performed an empathic accuracy task in which they watched videos of people discussing emotional events from their life and rated how they thought the people in the videos were feeling.
Although all participants were healthy adults who did not have autism, the researchers looked at whether differences in social cognitive expertise affected response to oxytocin. Social competency was measured using the Autism Spectrum Quotient (AQ), a common self-report instrument that predicts social cognitive performance. Researchers hypothesized that oxytocin and AQ would interact to predict social cognitive performance. Results showed that oxytocin improved empathic accuracy, but only in those individuals who were less socially proficient.
“Oxytocin is widely believed to make all people more empathic and understanding of others,” said Jennifer Bartz, PhD, Assistant Professor, Psychiatry, Mount Sinai School of Medicine, and lead author of the study. “Our study contradicts that. Instead, oxytocin appears to be helpful only for those who are less socially proficient.”
More socially proficient participants performed well on the empathic accuracy task regardless of whether they were on oxytocin or placebo. By contrast, less socially proficient participants performed poorly on placebo but significantly better on oxytocin. In fact, on oxytocin, their empathic accuracy performance was identical to that of the socially proficient participants.
“Our data show that oxytocin selectively improves social cognition in people who are less socially proficient, but had little impact on more socially proficient individuals,” continued Dr. Bartz. “While more research is required, these results highlight the potential oxytocin holds for treating social deficits in people with disorders marked by deficits in social functioning like autism.”
Dr. Bartz and her colleagues also received a grant through the American Recovery and Reinvestment Act (ARRA), the federal government stimulus package, to continue her research on the impact of oxytocin beyond this study, specifically in adults with autism spectrum disorders.
About The Mount Sinai Medical Center
The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Mount Sinai School of Medicine. Established in 1968, Mount Sinai School of Medicine is one of few medical schools embedded in a hospital in the United States. It has more than 3,400 faculty in 32 departments and 15 institutes, and ranks among the top 20 medical schools both in National Institute of Health funding and by U.S. News & World Report. The school received the 2009 Spencer Foreman Award for Outstanding Community Service from the Association of American Medical Colleges.
The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation’s oldest, largest and most-respected voluntary hospitals. In 2009, U.S. News & World Report ranked The Mount Sinai Hospital among the nation’s top 20 hospitals based on reputation, patient safety, and other patient-care factors. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 530,000 outpatient visits took place.
For more information, visit www.mountsinai.org. Follow us on Twitter @mountsinainyc.
Mount Sinai Press Office | Newswise Science News
NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases
Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...
The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...
At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.
When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...
At the ILA Berlin, hall 4, booth 202, Fraunhofer FHR will present two radar sensors for navigation support of drones. The sensors are valuable components in the implementation of autonomous flying drones: they function as obstacle detectors to prevent collisions. Radar sensors also operate reliably in restricted visibility, e.g. in foggy or dusty conditions. Due to their ability to measure distances with high precision, the radar sensors can also be used as altimeters when other sources of information such as barometers or GPS are not available or cannot operate optimally.
Drones play an increasingly important role in the area of logistics and services. Well-known logistic companies place great hope in these compact, aerial...
16.03.2018 | Event News
13.03.2018 | Event News
08.03.2018 | Event News
16.03.2018 | Earth Sciences
16.03.2018 | Physics and Astronomy
16.03.2018 | Life Sciences